ATOS / Pharmaceutical M&A thriving as global dealmaking struggles to stay healthy

Atossa Therapeutics Inc (NASDAQ:ATOS)'s selective estrogen receptor modulator (Z)-endoxifen is being evaluated in a Phase 2 study aimed at preventing more_horizontal

Analysts at Cantor Fitzgerald have initiated coverage on Atossa Therapeutics Inc (NASDAQ:ATOS) with an ‘Overweight' rating and a $5 price target on more_horizontal

Atossa Therapeutics Inc (NASDAQ:ATOS) is targeting three different stages of the breast cancer continuum with its proprietary oral form of Endoxifen, more_horizontal

Atossa Therapeutics Inc (NASDAQ:ATOS) unveiled its second quarter financial results highlighted by a strong balance sheet to support the company in co more_horizontal

Atossa Therapeutics Inc (NASDAQ:ATOS) has received what's known as a no objection letter from Health Canada in response to its clinical trial applicat more_horizontal

Analysts at Maxim Group have reiterated a 'buy' rating on Atossa Therapeutics Inc (NASDAQ:ATOS) shares after the biotech recently announced an enroll more_horizontal

Atossa Therapeutics Inc (NASDAQ:ATOS) announced that 170 patients have been enrolled across its ongoing Phase 2 Karisma-Endoxifen study of its oral fo more_horizontal

When it comes to potentially profitable penny stocks, some can create unimaginable fortunes for patient investors. Others, not so much. more_horizontal